Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients.
BACKGROUND: Autoantibodies against CD28 have been found in patients with autoimmune and atopic diseases. These antibodies may act as superagonists and activate T cells but may also be antagonistic or induce immunosuppressive effects by activating regulatory T cells. Autoimmunity in melanoma patients...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3590176?pdf=render |
id |
doaj-a9ca8d9785de429ba14822cdf238bfc8 |
---|---|
record_format |
Article |
spelling |
doaj-a9ca8d9785de429ba14822cdf238bfc82020-11-25T02:33:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0183e5808710.1371/journal.pone.0058087Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients.Rebecca KörnerKlaus-Dieter PreussNatalie FadleDarius MadjidiFrank NeumannLennart BergelerStefan GräberCornelia S L MüllerFrank GrünhageMichael PfreundschuhFrank LammertThomas VogtClaudia PföhlerBACKGROUND: Autoantibodies against CD28 have been found in patients with autoimmune and atopic diseases. These antibodies may act as superagonists and activate T cells but may also be antagonistic or induce immunosuppressive effects by activating regulatory T cells. Autoimmunity in melanoma patients has been discussed controversially. OBJECTIVE: We investigated 230 melanoma patients for the occurrence of CD28 antibodies and the effect of the latter on overall and progress-free survival. METHODS: We constructed an ELISA assay to measure CD28 serum antibodies. 230 patients with melanoma and a control-group of 625 patients consistent of 212 patients with virus hepatitis b or c, 149 patients with allergies, 78 patients with psoriasis, 46 patients with plasmocytoma and 140 healthy blood donors were investigated for the occurrence of CD28 antibodies. RESULTS: CD28 abs occur at a higher percentage in patients with melanoma and in patients with viral hepatitis than in other groups investigated (p<0.001). Occurrence of CD28 abs is significantly higher in patients receiving interferons independent from the underlying disease (p<0.001). In vitro CD28 serum antibodies have an inhibitory effect on the CD28 receptor as they lead to reduced stimulation of Jurkat cells. Presence of CD28 was correlated with a higher risk of dying from melanoma (p = 0.043), but not with a significantly shortened overall survival or progression-free survival. CONCLUSION: Interferon therapy appears to induce the production of CD28 abs. In light of reports that these CD28 abs induce immunosuppressive Tregs and - as our data show - that they are inhibitors of CD28 receptor mediated stimulation, the continuation of therapies with interferons in melanoma patients developing CD28 antibodies should be critically reconsidered, since our data indicate a worse outcome of patients with CD28 abs.http://europepmc.org/articles/PMC3590176?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rebecca Körner Klaus-Dieter Preuss Natalie Fadle Darius Madjidi Frank Neumann Lennart Bergeler Stefan Gräber Cornelia S L Müller Frank Grünhage Michael Pfreundschuh Frank Lammert Thomas Vogt Claudia Pföhler |
spellingShingle |
Rebecca Körner Klaus-Dieter Preuss Natalie Fadle Darius Madjidi Frank Neumann Lennart Bergeler Stefan Gräber Cornelia S L Müller Frank Grünhage Michael Pfreundschuh Frank Lammert Thomas Vogt Claudia Pföhler Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients. PLoS ONE |
author_facet |
Rebecca Körner Klaus-Dieter Preuss Natalie Fadle Darius Madjidi Frank Neumann Lennart Bergeler Stefan Gräber Cornelia S L Müller Frank Grünhage Michael Pfreundschuh Frank Lammert Thomas Vogt Claudia Pföhler |
author_sort |
Rebecca Körner |
title |
Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients. |
title_short |
Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients. |
title_full |
Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients. |
title_fullStr |
Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients. |
title_full_unstemmed |
Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients. |
title_sort |
serum antibodies against cd28-- a new potential marker of dismal prognosis in melanoma patients. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
BACKGROUND: Autoantibodies against CD28 have been found in patients with autoimmune and atopic diseases. These antibodies may act as superagonists and activate T cells but may also be antagonistic or induce immunosuppressive effects by activating regulatory T cells. Autoimmunity in melanoma patients has been discussed controversially. OBJECTIVE: We investigated 230 melanoma patients for the occurrence of CD28 antibodies and the effect of the latter on overall and progress-free survival. METHODS: We constructed an ELISA assay to measure CD28 serum antibodies. 230 patients with melanoma and a control-group of 625 patients consistent of 212 patients with virus hepatitis b or c, 149 patients with allergies, 78 patients with psoriasis, 46 patients with plasmocytoma and 140 healthy blood donors were investigated for the occurrence of CD28 antibodies. RESULTS: CD28 abs occur at a higher percentage in patients with melanoma and in patients with viral hepatitis than in other groups investigated (p<0.001). Occurrence of CD28 abs is significantly higher in patients receiving interferons independent from the underlying disease (p<0.001). In vitro CD28 serum antibodies have an inhibitory effect on the CD28 receptor as they lead to reduced stimulation of Jurkat cells. Presence of CD28 was correlated with a higher risk of dying from melanoma (p = 0.043), but not with a significantly shortened overall survival or progression-free survival. CONCLUSION: Interferon therapy appears to induce the production of CD28 abs. In light of reports that these CD28 abs induce immunosuppressive Tregs and - as our data show - that they are inhibitors of CD28 receptor mediated stimulation, the continuation of therapies with interferons in melanoma patients developing CD28 antibodies should be critically reconsidered, since our data indicate a worse outcome of patients with CD28 abs. |
url |
http://europepmc.org/articles/PMC3590176?pdf=render |
work_keys_str_mv |
AT rebeccakorner serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT klausdieterpreuss serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT nataliefadle serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT dariusmadjidi serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT frankneumann serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT lennartbergeler serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT stefangraber serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT corneliaslmuller serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT frankgrunhage serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT michaelpfreundschuh serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT franklammert serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT thomasvogt serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients AT claudiapfohler serumantibodiesagainstcd28anewpotentialmarkerofdismalprognosisinmelanomapatients |
_version_ |
1724813485025525760 |